CA2938581C - Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof - Google Patents
Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof Download PDFInfo
- Publication number
- CA2938581C CA2938581C CA2938581A CA2938581A CA2938581C CA 2938581 C CA2938581 C CA 2938581C CA 2938581 A CA2938581 A CA 2938581A CA 2938581 A CA2938581 A CA 2938581A CA 2938581 C CA2938581 C CA 2938581C
- Authority
- CA
- Canada
- Prior art keywords
- antipsychotic drug
- pharmaceutical composition
- inhibitor
- antipsychotic
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461937223P | 2014-02-07 | 2014-02-07 | |
| US61/937,223 | 2014-02-07 | ||
| PCT/US2015/014893 WO2015120317A1 (en) | 2014-02-07 | 2015-02-06 | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2938581A1 CA2938581A1 (en) | 2015-08-13 |
| CA2938581C true CA2938581C (en) | 2023-02-28 |
Family
ID=52589782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2938581A Active CA2938581C (en) | 2014-02-07 | 2015-02-06 | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9782398B2 (enExample) |
| EP (2) | EP3102239A1 (enExample) |
| JP (4) | JP6718376B2 (enExample) |
| KR (1) | KR102328058B1 (enExample) |
| CN (3) | CN106061506A (enExample) |
| AU (1) | AU2015213778B2 (enExample) |
| CA (1) | CA2938581C (enExample) |
| ES (1) | ES3062021T3 (enExample) |
| IL (1) | IL247127B (enExample) |
| MX (1) | MX378664B (enExample) |
| NZ (2) | NZ760790A (enExample) |
| RU (2) | RU2757221C2 (enExample) |
| WO (1) | WO2015120317A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ725826A (en) * | 2014-05-06 | 2023-05-26 | Neurocrine Biosciences Inc | Vmat2 inhibitors for the treatment of hyperkinetic movement disorders |
| US9714246B2 (en) * | 2015-02-06 | 2017-07-25 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
| RS61645B1 (sr) | 2015-10-30 | 2021-04-29 | Neurocrine Biosciences Inc | Valbenazin ditozilat i njihovi polimorfi |
| JP6869988B2 (ja) | 2015-12-23 | 2021-05-12 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | （Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法 |
| US10442800B2 (en) | 2016-06-29 | 2019-10-15 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal forms of NBI-98854, preparation method and use thereof |
| WO2018102673A1 (en) * | 2016-12-02 | 2018-06-07 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating schizophrenia or schizoaffective disorder |
| CN115813888A (zh) | 2016-12-20 | 2023-03-21 | 罗曼治疗系统股份公司 | 包含阿塞那平的透皮治疗系统 |
| EP3558276B1 (en) | 2016-12-20 | 2024-11-06 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| CA3051830A1 (en) | 2017-01-27 | 2018-08-02 | Neurocrine Bioscienes, Inc. | Methods for the administration of certain vmat2 inhibitors |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| WO2019002204A1 (en) | 2017-06-26 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER |
| CA3076000A1 (en) | 2017-09-21 | 2019-03-28 | Neurocrine Biosciences, Inc. | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| JP2021502959A (ja) | 2017-10-10 | 2021-02-04 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| JP7212958B2 (ja) | 2017-12-26 | 2023-01-26 | ▲蘇▼州科睿思制▲葯▼有限公司 | バルベナジントシル酸塩の結晶形及びその製造方法並びに用途 |
| CA3097189A1 (en) | 2018-04-25 | 2019-10-31 | Shinkei Therapeutics Llc | Tetrabenazine transdermal delivery device |
| WO2019212185A1 (ko) * | 2018-05-04 | 2019-11-07 | 한국원자력의학원 | 아리피프라졸을 유효성분으로 함유하는 방사선 민감성 증진용 조성물 |
| AU2019287524A1 (en) | 2018-06-14 | 2020-12-24 | Neurocrine Biosciences, Inc. | VMAT2 inhibitor compounds, compositions, and methods relating thereto |
| AU2019291060B2 (en) | 2018-06-20 | 2024-09-05 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| US12329862B2 (en) | 2018-06-20 | 2025-06-17 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| MA53239A (fr) * | 2018-08-15 | 2022-05-04 | Neurocrine Biosciences Inc | Procédés d'administration de certains inhibiteurs de vmat2 |
| WO2020188551A1 (en) * | 2019-03-20 | 2020-09-24 | Bol Pharma Ltd. | Methods and compositions for treating autism spectrum disorder and associated disorders |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| CA3220946A1 (en) * | 2021-06-30 | 2023-01-05 | Angel S. Angelov | Valbenazine for use in the add-on treatment of schizophrenia |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5777697A (en) * | 1980-11-04 | 1982-05-15 | Nippon Zoki Pharmaceut Co Ltd | Physiologically active substance nsq |
| JPS57209225A (en) * | 1981-06-18 | 1982-12-22 | Yamasa Shoyu Co Ltd | Antitumor activity intensifier |
| US5204329A (en) * | 1990-06-11 | 1993-04-20 | Du Pont Merck Pharmaceutical Company | Treatment of organ transplantation rejection |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| WO2000024399A1 (en) * | 1998-10-23 | 2000-05-04 | Sepracor Inc. | Compositions and methods employing r(-) fluoxetine and other active ingredients |
| GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| NZ566011A (en) * | 2005-08-06 | 2011-01-28 | Biovail Lab Internat Barbados Srl | 3, 11b cis dihydrotetrabenazine for the treatment of schizophrenia and other psychoses |
| EP2081929B1 (en) | 2006-11-08 | 2013-01-09 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto |
| WO2011019956A2 (en) * | 2009-08-12 | 2011-02-17 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| GB2463452A (en) * | 2008-09-08 | 2010-03-17 | Cambridge Lab | Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof |
| CA2972242A1 (en) * | 2008-09-18 | 2010-04-22 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EP3351247A1 (en) * | 2010-06-01 | 2018-07-25 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
-
2015
- 2015-02-06 CN CN201580009498.0A patent/CN106061506A/zh active Pending
- 2015-02-06 JP JP2016549493A patent/JP6718376B2/ja not_active Expired - Fee Related
- 2015-02-06 RU RU2016135930A patent/RU2757221C2/ru active
- 2015-02-06 ES ES21216409T patent/ES3062021T3/es active Active
- 2015-02-06 CA CA2938581A patent/CA2938581C/en active Active
- 2015-02-06 NZ NZ760790A patent/NZ760790A/en unknown
- 2015-02-06 CN CN202110257206.2A patent/CN113368110A/zh active Pending
- 2015-02-06 MX MX2016010071A patent/MX378664B/es unknown
- 2015-02-06 EP EP15706596.2A patent/EP3102239A1/en not_active Withdrawn
- 2015-02-06 KR KR1020167024297A patent/KR102328058B1/ko active Active
- 2015-02-06 WO PCT/US2015/014893 patent/WO2015120317A1/en not_active Ceased
- 2015-02-06 RU RU2021128797A patent/RU2021128797A/ru unknown
- 2015-02-06 US US15/116,786 patent/US9782398B2/en active Active
- 2015-02-06 CN CN202110257547.XA patent/CN113413385A/zh active Pending
- 2015-02-06 EP EP21216409.9A patent/EP4049681B1/en active Active
- 2015-02-06 AU AU2015213778A patent/AU2015213778B2/en active Active
- 2015-02-06 NZ NZ723107A patent/NZ723107A/en unknown
-
2016
- 2016-08-04 IL IL247127A patent/IL247127B/en active IP Right Grant
-
2017
- 2017-09-11 US US15/701,311 patent/US20180085364A1/en not_active Abandoned
-
2019
- 2019-01-16 US US16/248,855 patent/US20190381029A1/en not_active Abandoned
- 2019-05-07 JP JP2019087459A patent/JP2019116515A/ja not_active Withdrawn
-
2020
- 2020-03-13 US US16/817,723 patent/US20200206215A1/en not_active Abandoned
-
2021
- 2021-03-02 JP JP2021032320A patent/JP2021080294A/ja active Pending
-
2023
- 2023-11-17 JP JP2023195803A patent/JP2024003253A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2938581C (en) | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof | |
| US20190015396A1 (en) | Vmat2 inhibitors for treating neurological diseases or disorders | |
| US9624208B2 (en) | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels | |
| JP7282082B2 (ja) | 置換ピリミジンピペラジン化合物及びその使用 | |
| KR20250029267A (ko) | 과다운동성 운동 장애의 치료를 위한 vmat2 억제제 | |
| US20090306040A1 (en) | Mono and Combination Therapy of M1/M4 Agonist (Sabcomeline) for Treatment of Negative Symptoms of Schizophrenia | |
| JP2018076365A (ja) | 中枢神経系疾患の治療に有用なトリアゾロ−ピラジン誘導体 | |
| US20090258084A1 (en) | Mono and Combination Therapy with a M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Cognitive Disorders in Schizophrenia | |
| WO2007111983A2 (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders | |
| HK40079434A (en) | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof | |
| HK40062589A (en) | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof | |
| RU2508106C2 (ru) | Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии | |
| WO2024059659A1 (en) | Cycloalkyl carboxylic acid derivatives as inhibitors of glycogen synthase 1 (gys1) and methods of use thereof | |
| RU2508096C2 (ru) | Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии | |
| HK40120047A (zh) | Kv7通道激活剂组合物和使用方法 | |
| HK40119317A (zh) | Kv7通道激活剂组合物和使用方法 | |
| HK40118422A (zh) | Kv7通道激活剂组合物和使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200115 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250131 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250131 |